Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRONGER: Atorvastatin for Long COVID Neurological Symptoms
NCT04904536Phase 3Active, not recruiting
- Sponsor
- The George Institute for Global Health
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atorvastatin in post-acute sequelae of SARS-CoV-2 infection (PASC) (2 arms), sponsored by The George Institute for Global Health. Primary endpoint: Neurological Recovery assessed on the oral Symbol Digit Modalities Test (SDMT) at 12 months. Started Mar 2022; status: active, not recruiting.
02
Drugs
atorvastatin
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT04904536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04904536.